Systemic Immun Inflamation Score Corelation in Postoperative Patients Prognosis

NCT07544719 | Not Yet Recruiting

• 1 other identifier: MEAH-SII-ICU-2026-01
• Study Type: observational
• Target: 150
• Locations: 0 countries
• Sites: N/A

Brief Summary

The Systemic Immuno-Inflammation Index (SII) is a ratio derived from complete blood count parameters (neutrophils, lymphocytes, platelets) and is a non-invasive and easily calculable biomarker. The SIPI effectively reflects both local and systemic inflammatory responses in the human body. It has been used to predict and evaluate the prognosis of various solid tumors such as gastric cancer, non-small cell lung cancer, and colorectal cancer. Furthermore, the SIPI has been shown to have significant prognostic value in cardiovascular and cerebrovascular diseases. In this study, the SIPI will be calculated using laboratory data at the time of admission to the intensive care unit, and the relationship between the obtained values and the 30-day mortality status of the patients will be analyzed.

Conditions

Geriatric Anesthesia; Postop Adult ICU Patients

Outcome Measures

Primary Outcomes (1)

• Measuring the Systemic Immune-Inflammation Index (SII) in postoperative patients to see the parameter's predictibility of 30-day mortality

  In geriatric patients admitted to the intensive care unit after surgery, the Systemic Immune-Inflammation Index (SII) is a significant biomarker for predicting 30-day mortality.

  Postoperative day 1

Eligibility Criteria

• Age: 65 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

65 years of age or older postoperative patients

You may qualify if:

• The patient must be 65 years of age or older (in the geriatric age group),
• Admitted to the intensive care unit after elective or emergency surgery
• Have access to complete blood count (hemogram) data (neutrophils, lymphocytes, platelets) during their stay in the intensive care unit
• Be able to undergo 30-day mortality monitoring from the date of admission to the intensive care unit
• Have provided informed consent from the patient or their legal representative.

You may not qualify if:

• Patients under 65 years of age
• Patients admitted to the intensive care unit for non-surgical reasons (e.g., trauma, medical intensive care indications)
• Patients with deficient neutrophil, lymphocyte, or platelet counts upon admission to the intensive care unit
• Patients with a history of malignancy, hematological disease, or immunosuppressive therapy
• Terminally ill palliative patients
• Patients who refuse informed consent.

Sponsors & Collaborators

• Malatya Egitim Ve Arastirma Hastanesi: lead

Related Publications (2)

• Chen JH, Zhai ET, Yuan YJ, Wu KM, Xu JB, Peng JJ, Chen CQ, He YL, Cai SR. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017 Sep 14;23(34):6261-6272. doi: 10.3748/wjg.v23.i34.6261.

  PMID: 28974892 RESULT

• Zeng QY, Qin Y, Shi Y, Mu XY, Huang SJ, Yang YH, Liu SM, An ZM, Li SQ. Systemic immune-inflammation index and all-cause and cause-specific mortality in sarcopenia: a study from National Health and Nutrition Examination Survey 1999-2018. Front Immunol. 2024 Apr 4;15:1376544. doi: 10.3389/fimmu.2024.1376544. eCollection 2024.

  PMID: 38638440 RESULT

Central Study Contacts

Ayşe Yılkınç Tekirdaş

CONTACT

+905395721741; ylknc.ys.44@hotmail.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 30 Days
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor

Study Record Dates

• First Submitted: April 9, 2026
• First Posted: April 22, 2026
• Study Start (Estimated): June 15, 2026
• Primary Completion (Estimated): July 15, 2026
• Study Completion (Estimated): July 30, 2026
• Last Updated: April 22, 2026

Record last verified: 2026-01